Hemanext Secures NIH Grant to Enhance Blood Management Technology
Hemanext Inc. Receives Significant NIH Grant
Hemanext Inc has been awarded a three-year Small Business Innovation Research Grant (SBIR) Phase II, aimed at enhancing clinical initiatives related to hypoxically stored red blood cells. This promising project is titled, "Efficacy of Hypoxic Red Blood Cells Processed with the Hemanext ONE System in Patients with Sickle Cell Anemia." The grant focuses on the potential benefits of these specialized blood products for patients suffering from this challenging condition.
Addressing the Needs of Sickle Cell Anemia Patients
Despite the emergence of new therapies, including pharmacologic and gene therapies, many patients with sickle cell disease (SCD) still struggle to access adequate treatment options. They remain reliant on regular red blood cell (RBC) transfusions to maintain their health. Unfortunately, this population faces significant challenges, as typical RBC transfusions may not always meet their specific health needs. Hemanext’s approach with hypoxically stored red blood cells (HRBC) represents a potential breakthrough in transfusion medicine.
Clinical Trial Overview
The clinical trial linked to the grant is designed to be a multi-center, randomized, controlled study. It will include participants aged seven years and older. The primary focus of this research will be to measure the efficacy of HRBC by looking at the decline rate of %Hemoglobin A and understanding how these specialized blood products affect patients’ transfusion needs. This thorough review will also encompass various clinical and laboratory parameters alongside patient quality of life evaluations.
Investigator Insights
Dr. Laurel Omert, the Chief Medical Officer at Hemanext, expressed her enthusiasm for collaborating with leading experts in the field. She stated, "I am delighted to be able to work with a group of such distinguished investigators in the field of sickle cell anemia to study the effect of large volume red blood cell exchange transfusions of HRBC in this underserved population." Her commitment to improving care options for these patients is truly commendable.
Significant Milestone for Hemanext
Andrew Dunham, the CEO of Hemanext, shared his thoughts on this important achievement. "This award marks a significant milestone for our team and validates the promise of our approach to transform transfusion medicine. We are honored and excited to receive this NIH SBIR grant, which underscores the significance of our work and its potential to address unmet clinical needs." This grant strengthens the foundation of Hemanext’s mission to enhance transfusion therapies and patient outcomes.
Regulatory Progress for HEMANEXT ONE
HEMANEXT ONE, Hemanext's flagship product, is a pioneering device designed to improve the quality of RBCs crucial for patients reliant on transfusions. It received marketing authorization via the U.S. Food and Drug Administration’s De Novo process in 2023 and has been CE marked since 2021. These approvals highlight the innovative nature and potential market impact of HEMANEXT ONE, marking it as a significant advancement in transfusion technology.
Commitment to Quality and Safety
Based in Lexington, MA, Hemanext is dedicated to revolutionizing blood transfusion practices through rigorous research and development focused on hypoxically stored red blood cells. The company strives to enhance the quality, safety, and efficacy of transfusion solutions, aiming to improve the standard of care for patients worldwide.
Contacting Hemanext
If you are interested in learning more about Hemanext and their groundbreaking work, you can reach out to:
Robert Haime, Vice President, Commercial
(781) 301-7474
Frequently Asked Questions
What is the primary focus of the NIH grant awarded to Hemanext Inc.?
The grant focuses on enhancing the efficacy of hypoxically stored red blood cells processed with the Hemanext ONE System for patients with sickle cell anemia.
How will the clinical trial evaluate the HRBC treatment?
The trial will measure the efficacy of HRBC by assessing the decline in %Hemoglobin A and its impact on reducing patients’ transfusion needs.
Who is leading the clinical trial's research team?
The clinical trial is led by Dr. Laurel Omert, with Dr. Biree Andemariam and Dr. Enrico Novelli serving as co-Principal Investigators.
What milestones has HEMANEXT ONE achieved recently?
HEMANEXT ONE received FDA marketing authorization and was CE marked, validating its effectiveness and potential in transfusion medicine.
How can one get in touch with Hemanext for more information?
For inquiries, contact Robert Haime, Vice President, Commercial, at (781) 301-7474.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.